Evidence map›Paper›PMID 31686242›Full record

ArticleMetabolomics : Official journal of the Metabolomic Society2019

A metabolic profile of routine needle biopsies identified tumor type specific metabolic signatures for breast cancer stratification: a pilot study.

Narumi Harada-Shoji, Tomoyoshi Soga, Hiroshi Tada, Minoru Miyashita, Mutsuo Harada, Gou Watanabe, Yohei Hamanaka, Akiko Sato, Takashi Suzuki, Akihiko Suzuki and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolomics : Official journal of the Metabolomic Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Narumi Harada-ShojiDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. n.harada@med.tohoku.ac.jp.
Tomoyoshi SogaInstitute for Advanced Biosciences, Keio University, Yamagata, Japan.
Hiroshi TadaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Minoru MiyashitaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Mutsuo HaradaDepartment of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Gou WatanabeDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yohei HamanakaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Akiko SatoDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takashi SuzukiDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Akihiko SuzukiDepartment of Breast and Endocrine Surgery, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Takanori IshidaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JPKeio University · JPThe University of Tokyo · JPTohoku Medical and Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMetabolomics has recently emerged as a tool for understanding comprehensive tumor-associated metabolic dysregulation. However, only limited application of this technology has been introduced into the clinical setting of breast cancer.

objectivesThe aim of this study was to determine the feasibility of metabolome analysis using routine CNB/VAB samples from breast cancer patients and to elucidate metabolic signatures using metabolic profiling.

methodsAfter breast cancer screenings, 20 consecutive patients underwent CNB/VAB, and diagnosed with benign, DCIS and IDC by histology. Metabolome analysis was performed using CE-MS. Differential metabolites were then analyzed and evaluated with MetaboAnalyst 4.0.

resultsWe measured 116-targeted metabolites involved in energy metabolism. Principal component analysis and unsupervised hierarchical analysis revealed a distinct metabolic signature unique to namely "pure" IDC samples, whereas that of DCIS was similar to benign samples. Pathway analysis unveiled the most affected pathways of the "pure" IDC metabotype, including "pyrimidine," "alanine, aspartate, and glutamate" and "arginine and proline" pathways.

conclusionsOur proof-of-concept study demonstrated that CE-MS-based CNB/VAB metabolome analysis is feasible for implementation in routine clinical settings. The most affected pathways in this study may contribute to improved breast cancer stratification and precision medicine.

Indexed as

MetabolomicsAdultAgedAged, 80 and overBiopsy, NeedleBreast NeoplasmsFemaleHumansMiddle AgedPilot ProjectsBreast cancerCE–MSMetabolome analysisNeedle breast biopsy

Identifiers

PMID31686242
OpenAlexW2985835596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.